# US 2010/0168386 A1 · Fusion protein carrying neurotrophin across the blood-brain barrier, encoding gene and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168386 A1
- Document ID: US20100168386A1
- Status: Published application
- Kind: A1
- Application number: 12/442,527
- Filed: 2007-09-04
- Published: 2010-07-01
- Earliest claimed: 2006-09-25
- Inventors: Aimin Ji; Ou Che; Leilei Ma; Dan Su; Hanzhang Ma; Xiaodong Li; Liang Sun; Bingjun Wang; Zhongyi Zhang
- Web page: https://patentgrep.com/patent/US20100168386A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are fusion proteins which comprise a first region having at least 75% homology with the amino acid sequence of neurotrophin, and a second region, located at the C-terminal of the first region, having at least 75% homology with the amino acid sequence of protein transduction domain (PTD). Also provided is encoding gene and usage thereof. The fusion protein can translocate through cell membrane or even the blood-brain barrier (BBB). The fusion protein can be used to treat various central nervous system degenerative diseases and peripheral neuropathy.

## Claims

### Claim 1

A fusion protein for carrying neurotrophins across blood-brain barrier, comprising:
a first region having amino acid sequences which has at least about 75% homology with that of mature neurotrophin; and
a second region having amino acid sequences which has at least about 70% homology with that of native protein transduction domain
wherein said second region is located at the carboxyl terminal of said first region.

### Claim 2 (depends on 1)

The fusion protein for carrying neurotrophins across blood-brain barrier according to claim 1, wherein said first region has amino acid sequences having at least about 85% homology with that of mature neurotrophin, and said second region has amino acid sequences having at least about 85% homology of that of native protein transduction domain.

### Claim 3 (depends on 1)

The fusion protein for carrying neurotrophins across blood-brain barrier according to claim 1, wherein said first region is human nerve growth factor, brain-derived neurotrophic factor, neurotrophin 3, or neurotrophin 4/5.

### Claim 4 (depends on 1)

The fusion protein for carrying neurotrophins across blood-brain barrier according to claim 1, wherein said second region is from the PTD of a homologous heterotypic protein Antp originated from fruit fly, from the PTD of pVEC of type I membrane protein Cadherin from mice vascular endothelial cells, or from the PTD of HIV trans activator of transcription Tat.

### Claim 5 (depends on 1)

The fusion protein for carrying neurotrophins across blood-brain barrier according to claim 1, wherein said second region is immediately adjacent to said first region, or connects to said first region through intervening amino acids.

### Claim 6 (depends on 1)

The fusion protein for carrying neurotrophins across blood-brain barrier according to claim 1, wherein said first region is human brain-derived neurotrophic factor, said second region is homologous heterotypic protein Antp originated from fruit fly, and the fusion protein has a amino acid sequence presented in SEQ ID NO:1.

### Claim 7 (depends on 6)

A nucleotide sequence encoding the fusion protein of claim 6, wherein said nucleotide sequence has a sequence presented in SEQ ID NO:2 or a complementary sequence thereof.

### Claim 8 (depends on 7)

An expression vector comprising the nucleotide sequence of claim 7.

### Claim 9 (depends on 8)

A host cell comprising the expression vector of claim 8.

### Claim 10 (depends on 1)

Usage of fusion protein of claim 1 in the preparation of medicines for treating neurotrophins related diseases.
